Long-Term Denosumab Treatment Reduces Nonvertebral Fractures in Osteoporosis
Compared with the first 3 years of denosumab treatment, a longer duration of denosumab therapy was associated with further decrease in nonvertebral fracture rate, which was sustained through 10 years of treatment.
